<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
pmid: 23034406
Sorafenib and sunitinib are oral tyrosine kinase inhibitors, commonly used in the treatment of metastatic renal cell carcinoma. Known adverse events associated with tyrosine kinase inhibitors include hypertension and palmarplantar erythrodysesthesia. We report two cases of acute pancreatitis associated with tyrosine kinase inhibitors.
Niacinamide, Indoles, Phenylurea Compounds, Middle Aged, Protein-Tyrosine Kinases, Sorafenib, Kidney Neoplasms, Pancreatitis, Sunitinib, Humans, Female, Pyrroles, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Aged
Niacinamide, Indoles, Phenylurea Compounds, Middle Aged, Protein-Tyrosine Kinases, Sorafenib, Kidney Neoplasms, Pancreatitis, Sunitinib, Humans, Female, Pyrroles, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Aged
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 20 | |
popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |